ArticleArthritis research & therapy2010
Work disability remains a major problem in rheumatoid arthritis in the 2000s: data from 32 countries in the QUEST-RA study.
Article in Arthritis research & therapy, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 114 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
114 citing papers in PubMed, 6 syntheses or guidelines pooled it, 284 citations in OpenAlex.
- The Effects of Patient Education on Psychological Status and Clinical Outcomes in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis.Frontiers in psychiatry · 2022Pooled it
- A Systematic Review of Job Loss Prevention Interventions for Persons with Inflammatory Arthritis.Journal of occupational rehabilitation · 2021Pooled it
- Diagnostic accuracy of anti-keratin antibody for rheumatoid arthritis: a meta-analysis.Clinical rheumatology · 2019Pooled it
- Modeled Health Economic Impact of a Hypothetical Certolizumab Pegol Risk-Sharing Scheme for Patients with Moderate-to-Severe Rheumatoid Arthritis in Finland.Advances in therapy · 2017Pooled it
- Comparative effectiveness of biologics for the management of rheumatoid arthritis: systematic review and network meta-analysis.Clinical rheumatology · 2017Pooled it
- My treatment approach to rheumatoid arthritis.Mayo Clinic proceedings · 2012Guideline
- Patient-reported outcomes of upadacitinib versus abatacept in patients with rheumatoid arthritis and an inadequate response to biologic disease-modifying antirheumatic drugs: 12- and 24-week results of a phase 3 trial.Arthritis research & therapy · 2022Trial
- Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: results from SELECT-NEXT.Arthritis research & therapy · 2019Trial
- Effects of upadacitinib on patient-reported outcomes: results from SELECT-BEYOND, a phase 3 randomized trial in patients with rheumatoid arthritis and inadequate responses to biologic disease-modifying antirheumatic drugs.Arthritis research & therapy · 2019Trial
- Efficacy of a Work Disability Prevention Program for People with Rheumatic and Musculoskeletal Conditions: A Single-Blind Parallel-Arm Randomized Controlled Trial.Arthritis care & research · 2018Trial
- One Year Effects of a Workplace Integrated Care Intervention for Workers with Rheumatoid Arthritis: Results of a Randomized Controlled Trial.Journal of occupational rehabilitation · 2017Trial
- Process Evaluation of a Workplace Integrated Care Intervention for Workers with Rheumatoid Arthritis.Journal of occupational rehabilitation · 2016Trial
- Tofacitinib or adalimumab versus placebo: patient-reported outcomes from a phase 3 study of active rheumatoid arthritis.Rheumatology (Oxford, England) · 2016Trial
- Discordance between patient and physician assessments of global disease activity in rheumatoid arthritis and association with work productivity.Arthritis research & therapy · 2016Trial
- A goal management intervention for polyarthritis patients: rationale and design of a randomized controlled trial.BMC musculoskeletal disorders · 2013Trial
- Impact of socioeconomic status on disability in a longitudinal rheumatoid arthritis cohort.Internal medicine journal · 2026Article
- Plasma Proteomics Identifies Thousand-and-One-Amino Acid Kinase 3 as a Potential Biomarker of Rheumatoid Arthritis Activity and a Novel Therapeutic Target.Arthritis & rheumatology (Hoboken, N.J.) · 2026Article
- Filgotinib Effectiveness in Rheumatoid Arthritis: Observational Analysis of a Large Multicenter Cohort.Rheumatology and therapy · 2026Article
- Article
- Potential mechanisms of acupuncture treatment for rheumatoid arthritis: a study based on network topology and machine learning.Chinese medicine · 2025Article
54 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
49 authors at 20 institutions in 26 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionWork disability is a major consequence of rheumatoid arthritis (RA), associated not only with traditional disease activity variables, but also more significantly with demographic, functional, occupational, and societal variables. Recent reports suggest that the use of biologic agents offers potential for reduced work disability rates, but the conclusions are based on surrogate disease activity measures derived from studies primarily from Western countries.
methodsThe Quantitative Standard Monitoring of Patients with RA (QUEST-RA) multinational database of 8,039 patients in 86 sites in 32 countries, 16 with high gross domestic product (GDP) (>24K US dollars (USD) per capita) and 16 low-GDP countries (<11K USD), was analyzed for work and disability status at onset and over the course of RA and clinical status of patients who continued working or had stopped working in high-GDP versus low-GDP countries according to all RA Core Data Set measures. Associations of work disability status with RA Core Data Set variables and indices were analyzed using descriptive statistics and regression analyses.
resultsAt the time of first symptoms, 86% of men (range 57%-100% among countries) and 64% (19%-87%) of women <65 years were working. More than one third (37%) of these patients reported subsequent work disability because of RA. Among 1,756 patients whose symptoms had begun during the 2000s, the probabilities of continuing to work were 80% (95% confidence interval (CI) 78%-82%) at 2 years and 68% (95% CI 65%-71%) at 5 years, with similar patterns in high-GDP and low-GDP countries. Patients who continued working versus stopped working had significantly better clinical status for all clinical status measures and patient self-report scores, with similar patterns in high-GDP and low-GDP countries. However, patients who had stopped working in high-GDP countries had better clinical status than patients who continued working in low-GDP countries. The most significant identifier of work disability in all subgroups was Health Assessment Questionnaire (HAQ) functional disability score.
conclusionsWork disability rates remain high among people with RA during this millennium. In low-GDP countries, people remain working with high levels of disability and disease activity. Cultural and economic differences between societies affect work disability as an outcome measure for RA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.